Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gabapentin - Pfizer

Drug Profile

Gabapentin - Pfizer

Alternative Names: CI 945; GABAPEN; GOE 3450; Neurontin

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epilepsy; Neuralgia; Neuropathic pain; Postherpetic neuralgia
  • Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Bipolar disorders; Migraine; Spinal muscular atrophy

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 09 Jun 2010 First generic equivalent approved in USA for Postherpetic neuralgia
  • 26 Jul 2006 Registered for Epilepsy in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top